Evaluating the Effectiveness and Safety of a Shortened Rifapentine-Moxifloxacin Regimen in Treating Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review
DOI:
https://doi.org/10.19166/med.v15i2.10976Keywords:
Safety, efficacy, rifapentine, moxifloxacinAbstract
Background:
Prolonged treatment duration remains a key challenge in managing drug-sensitive pulmonary tuberculosis (DS-TB), contributing to poor adherence and treatment failure. Recent evidence suggests that regimens incorporating rifapentine and moxifloxacin (RPT+MOX) may allow for effective 4-month treatment courses.
Methods:
We conducted a systematic review and meta-analysis following PRISMA 2020 guidelines to evaluate the effectiveness and safety of shortened RPT+MOX regimens. PubMed, EMBASE, and Scopus were searched up to May 2025. Eligible studies included randomized trials or observational cohorts comparing shortened RPT+MOX regimens with standard 6-month therapies in patients with DS-TB. Outcomes included culture conversion at 8 weeks, relapse or treatment failure, and serious adverse events. Risk of bias was assessed using the ROBINS-I tool.
Result:
Five studies (three RCTs, two observational) met inclusion criteria. Pooled analysis showed no significant difference in risk for relapse or treatment failure (RR 0.79, 95% CI: 0.37–1.67), culture conversion (RR 1.16, 95% CI: 0.80–1.69), or serious adverse events (RR 0.92, 95% CI: 0.65–1.29) between RPT+MOX and standard regimens. Risk of bias ranged from minimal to moderate. The GRADE assessment supported high certainty of evidence.
Conclusions:
Shortened RPT+MOX regimens demonstrate comparable effectiveness and safety to standard 6-month treatment for DS-TB, supporting their use in appropriate settings. Further studies are warranted to assess long-term outcomes, real-world adherence, and feasibility across diverse populations.
References
1. Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, et al. Tuberculosis. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases [Internet]. 3rd ed. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 [cited 2025 Jun 3]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK525174/
2. Santosa A, Juniarti N, Pahria T, Susanti RD. Integrating narrative and bibliometric approaches to examine factors and impacts of tuberculosis treatment non-compliance. Multidiscip Respir Med. 2025 Feb 28;20(1):1016.
3. Jiang W, Dong D, Febriani E, Adeyi O, Fuady A, Surendran S, et al. Policy gaps in addressing market failures and intervention misalignments in tuberculosis control: prospects for improvement in China, India, and Indonesia. The Lancet Regional Health - Western Pacific. 2024 May;46:101045.
4. Chakaya JM, Harries AD, Marks GB. Ending tuberculosis by 2030—Pipe dream or reality? International Journal of Infectious Diseases. 2020 Mar;92:S51–4.
5. Ahmad Z, Tyagi S, Minkowski A, Peloquin CA, Grosset JH, Nuermberger EL. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. Am J Respir Crit Care Med. 2013 Jul 1;188(1):97–102.
6. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 May 6;384(18):1705–18.
7. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;n71.
8. Jindani A, Harrison TS, Nunn AJ, Phillips PPJ, Churchyard GJ, Charalambous S, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1599–608.
9. Conde MB, Mello FCQ, Duarte RS, Cavalcante SC, Rolla V, Dalcolmo M, et al. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. PLoS One. 2016;11(5):e0154778.
10. Louie JK, Agraz-Lara R, Velásquez GE, Phillips A, Szumowski JD. Experience With Four-Month Rifapentine and Moxifloxacin-Based Tuberculosis Treatment in San Francisco. Open Forum Infect Dis. 2024 Apr;11(4):ofae178.
11. Kurbatova EV, Whitworth WC, Peddareddy LP, Phillips PPJ, Scott NA, Bryant KE, et al. Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes. Emerg Infect Dis. 2025 Mar;31(3):467–76.
12. World Health Organization. WHO operational handbook on tuberculosis. Module 4: Treatment. Drug-susceptible tuberculosis treatment. In: 1st ed. World Health Organization; 2024.
13. Naidoo A, Naidoo K, McIlleron H, Essack S, Padayatchi N. A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis. J Clin Pharmacol. 2017 Nov;57(11):1369–86.
14. Johnson TM, Rivera CG, Lee G, Zeuli JD. Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 2024 Dec;37:100470.
15. Saktiawati AMI, Vasiliu A, Saluzzo F, Akkerman OW. Strategies to Enhance Diagnostic Capabilities for the New Drug-Resistant Tuberculosis (DR-TB) Drugs. Pathogens. 2024 Nov 28;13(12):1045.
16. Karnan A, Jadhav U, Ghewade B, Ledwani A, Shivashankar P. A Comprehensive Review on Long vs. Short Regimens in Multidrug-Resistant Tuberculosis (MDR-TB) Under Programmatic Management of Drug-Resistant Tuberculosis (PMDT). Cureus. 2024 Jan;16(1):e52706.
17. Mardhiyyah CA, Aprilio K, Sumarheni, Gnanasan S, Pitaloka DAE, Pradipta IS. Can we involve pharmacists as direct service providers for people with tuberculosis? A narrative review of current evidence. Exploratory Research in Clinical and Social Pharmacy. 2025 Sep;19:100613.
18. Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol. 2022 Nov;20(11):685–701.
19. An Y, Khun KE. Factors associated with incomplete tuberculosis preventive treatment: a retrospective analysis of six-years programmatic data in Cambodia. Sci Rep. 2024 Aug 9;14(1):18458.
20. Mancuso G, Midiri A, De Gaetano S, Ponzo E, Biondo C. Tackling Drug-Resistant Tuberculosis: New Challenges from the Old Pathogen Mycobacterium tuberculosis. Microorganisms. 2023 Sep 10;11(9):2277.
21. Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Disease Control Priorities, Third Edition (Volume 6): Major Infectious Diseases [Internet]. The World Bank; 2017 [cited 2025 Jun 5]. Available from: http://elibrary.worldbank.org/doi/book/10.1596/978-1-4648-0524-0
22. Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, et al. Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. Pharmaceutics. 2024 Feb 27;16(3):332.
23. Reynolds J, Heysell SK. Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):813–23.
24. Ventresca M, Schünemann HJ, Macbeth F, Clarke M, Thabane L, Griffiths G, et al. Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide. BMC Med Res Methodol. 2020 Dec;20(1):113.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Luthfia Ayu Wicaksana, Endy Amos Todo Hasudungan Sirait
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website). The final published PDF should be used and bibliographic details that credit the publication in this journal should be included.
